Promising results for CML
Tuesday, 09 December, 2008
Melbourne’s ChemGenex has released interim data of its Phase II/III trial of a compound for chronic myeloid leukaemia.
The trial involves 44 patients with the T315I mutation who have not responded to Novartis’ Glivec, or imatinib.
ChemGenex’s compound, omacetaxine mepesuccinate, showed good responses in chronic phase patients and was well tolerated, the company said.
The trial results were reported by trial investigator Jorge Cortes of the MD Anderson Cancer Center at a haematology conference in the US.
ChemGenex CEO Dr Greg Collier said the data would probably form part of the clinical section of the company’s new drug application to the US FDA next year.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
